From brain passage to cell adaptation: The road of human rabies vaccine development

Expert Review of Vaccines

Volumn 10, Issue 11, 2011, Pages 1597-1608

  Wu, Xianfu ^a   Smith, Todd G ^a   Rupprecht, Charles E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Lyssavirus; rabies; rabies vaccine; rabies virus; Vero cells

Indexed keywords

DIPLOID CELL VACCINE; DNA VACCINE; GLYCEROL; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MYELIN; PHENOL; POLIOMYELITIS VACCINE; PRIMARY HAMSTER KIDNEY CELL RABIES VACCINE; PROPIOLACTONE; PURIFIED DUCK EMBRYO CELL VACCINE; PURIFIED VERO CELL RABIES VACCINE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGENICITY; ATTENUATION; BACTERIUM CONTAMINATION; BRAIN TISSUE; CELL CULTURE; CROSS REACTION; CULTURE TECHNIQUE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG PURITY; DRUG SAFETY; DRUG STORAGE; ENCEPHALOMYELITIS; FERMENTATION; GOOD MANUFACTURING PRACTICE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INOCULATION; KIDNEY CELL CULTURE; MASS IMMUNIZATION; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RABIES; RABIES VIRUS; REVIEW; RISK ASSESSMENT; TROPISM; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION; VERO CELL; VIRION; VIRUS ISOLATION; VIRUS STRAIN;

ANIMALS; CELL CULTURE TECHNIQUES; DRUG DISCOVERY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RABIES; RABIES VACCINES; TECHNOLOGY, PHARMACEUTICAL; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 80455126038     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.140     Document Type: Review

References (106)

1. Pasteur L, Chamberland CE, Roux E. Methode pour prevenir la rage apres morsue (in French). C. R. Acad. Sci. 101, 765-774 (1885).
2. M. Pasteur on the virus of rabies, medical progress: medicine. JAMA 3, 40-41 (1884).
3. Constantine DG. Geographic translocaton of bats: known and potential problems. Emerg. Infect. Dis. 9, 17-21 (2003). (Pubitemid 36110197)
4. Marano N, Arguin PM, Pappaioanou M. Impact of globalization and animal trade on infectious disease ecology. Emerg. Infect. Dis. 13, 1807-1809 (2007). (Pubitemid 350248479)
5. Castrodale L, Walker V, Baldwin J, Hofmann J, Hanlon C. Rabies in a puppy imported from India to the USA. March 2007. Zoonoses Public Health 55, 427-430 (2008).
6. Meng S, Sun Y, Wu X et al. Evolutionary dynamics of rabies viruses highlights the importance of China rabies transmission in Asia. Virology 410, 403-409 (2011).
7. Malerczyk C, Nel LH, Gniel D, Blumberg L. Rabies in South Afica and the FIFA Soccer World Cup: travelers' awareness for an endemic but neglected disease. Hum. Vaccine 6, 385-389 (2010).
8. Yamamoto S, Iwasaki C, Oono H, Ninomiya K, Matsumura T. The first imported case of rabies into Japan in 36 years: a forgotton life-threatening disease. J. Travel Med. 15, 372-374 (2008).
9. Smith J, McElhinney L, Parsons G et al. Case report: rapid ante-mortem diagnosis of a human case of rabies imported into the UK from the Philippines. J. Med. Virol. 69, 150-155 (2003). (Pubitemid 35403667)
10. Watson EM. The negri bodies in rabies. J. Exp. Med. 17(1), 29-42 (1913).
11. The Pasteur treatment of hydrophobia. JAMA 17, 376-378 (1891).
12. Théodoridés J. Pasteur and rabies: the British connection. J. Royal Soc. Med. 82, 488-490 (1989).
13. Burke DS. Joseph-Alexandre Auzias- Turenne, Louis Pasteur, and early concepts of virulence, attenuation, and vaccination. Perspective Biol. Med. 39, 171-186 (1996). (Pubitemid 26067783)
14. Gelfand T. 11 January 1887, the day medicine changed: Joseph Grancher's defense of Pasteur's treatment for rabies. Bull. Hist. Med. 76, 698-718 (2002). (Pubitemid 41451070)
15. Fermi C. Über die Immunisierung gegen Wutkrankheit (in German). Z. Hyg. Infectionskrankh. 58, 233-276 (1908).
16. Semple D. The preparation of a safe and efficient antirabic vaccine. Sci. Mem. Med. Sanit. Dept. India. 44 (1911).
17. Sudarshan MK, Bhardwaj S, Mahendra BJ et al. An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects. Hum. Vaccines 4, 275-279 (2009).
18. Svet-Moldavskij G, Andjaparidze O, Unanov S et al. An allergen-free antirabies vaccine. Bull. World Health Organ. 32, 47-58 (1965).
19. Fuenzalida E, Palacios R, Borgono JM. Anti-rabies antibody responses in man to vaccine made from infected sucklingmouse brains. Bull. World Health Organ. 30, 431-436 (1964).
20. McKendrick AG. A ninth analytical review of reports from Pasteur Institute on the results of anti-rabies treatment. Bull. Hlth Org. 9, 31-78 (1940).
21. Greenwood M. Tenth report on data of antirabies treatment supplied by Pasteur Institute. Bull. Hlth Org. 12, 301-364 (1945).
22. Sellers TF. Rabies, the physician's dilemma. Am. J. Trop. Med. Hyg. 28, 453-456 (1948).
23. Bonito RF, de Oliveira NM, Nishioka Sde A. Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasiexperimental study. Rev. Soc. Bras. Med. Trop. 37, 7-9 (2004).
24. Goodpasture EW, Woodruff AM, Buddingh GJ. The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos. Science 74, 371-372 (1931).
25. Koprowski L, Cox HR. Studies on chick embryo adapted rabies virus: I. Culture characteristics and pathogenicity. J. Immunol. 60, 533-554 (1948).
26. Koprowski L, Black J. Studies on chick embryo adapted rabies virus: II. Pathogenicity for dogs and use of egg-adapted strains for vaccination purpose. J. Immunol. 64, 185-196 (1950).
27. Koprowski L, Black J. Studies on chick embryo adapted rabies virus: IV. Immunization of guinea-pigs and description of a potency control test. J. Immunol. 72, 79-84 (1954).
28. Koprowski L, Black J. Studies on chick embryo adapted rabies virus: V. Protection of animals with antiserum and living attenuated virus after exposure to street strain of rabies virus. J. Immunol. 72, 85-93 (1954).
29. Koprowski L, Black J, Nelsen DJ. Studies on chick embryo adapted rabies virus: VI. Further changes in pathogenic properties following prolonged cultivation in the developing chick embryo. J. Immunol. 72, 94-106 (1954).
30. Koprowski L, Black J. Studies on chick embryo adapted rabies virus: VII. Immunological responses of animals to vaccination with high egg passage Flury strain. J. Immunol. 72, 503-510 (1954).
31. Leach CN, Johnson HN. Human rabies, with special reference to virus distribution and titer. Am. J. Trop. Med. Hyg. 20, 335-340 (1940).
32. Fox JP, Koprowski H, Conwell DP, Black J, Gelfand HM. Study of antirabies immunization of man. Observations with HEP Flury and other vaccines, with and without hyperimmune serum, in primary and recall immunizations. Bull. Org. Mond. Sante. Bull. Wld Hlth Org. 17, 869-904 (1957).
33. Peck FB, Powell HM, Culbertson CG. A new antirabies vaccine for human use. Appl. Microbiol. 679-683 (1955).
34. Vodopija I, Clarke HF. Human vaccination against rabies. In: The Natural History of Rabies (2nd Edition). Baer GM (Ed.). CRC Press, FL, USA, 571-595 (1991).
35. Sabin AB. Experiments on the purification and concentration of the virus of poliomyelitis. J. Exp. Med. 56, 307-317 1932).
36. Enders JF, Robbins FC, Weller TH. Classics in infectious diseases: the cultivation of the poliomyelitis virus in tissue culture. Nobel lecture, delivered at the Karolinska Institute, Stockholm, Sweden, on Dec 11, 1954. Rev. Infect. Dis. 2, 493-504 (1980).
37. Enders JF, Weller TH, Robbins FC. Cultivation of Lansing strain of poliomyelitis virus in culture of various human embryonic tissues. Science 109, 85-87 (1949).
38. Norrby E. Nobel prize and the emerging virus concept. Arch. Virol. 153, 1109-1123 (2008).
39. Atanasiu P, Laurent C. Multiplication of the virus of rabies of dogs on a glial cell (mouse ependymoma) in tissue culture: histological aspect (in French). C. R. Hebd. Seances Acad. Sci. 245, 2562-2564 (1957).
40. Kissling RE. Growth of rabies virus in nonnervous tissue culture. Proc. Soc. Exp. Biol. Med. 98, 223-225 (1958).
41. Kissling RE, Reese DR. Anti-rabies vaccine of tissue culture origin. J. Immun. 91, 362-368 (1963).
42. Fenje P. A rabies vaccine from hamster kidney tissue cultures: preparation and evaluation in animals. Can. J. Microbiol. 6X 605-609 (1960).
43. Mitchell JR, Everest RE, Anderson GR. Sensitive procedure for detecting residual viable virus in inactivated rabies vaccine. Appl. Microbiol. 22, 600-603 (1971).
44. Sureau P. Rabies vaccine production in animal cell cultures. Adv. Biochem. Eng. Biotechnol. 34, 111-128 (1987).
45. Lin F, Zeng F, Lu L et al. The primary hamster kidney cell rabies vaccine: adaptation of viral strain, production of vaccine, and pre- and postexposure treatment. J. Infect. Dis. 147, 467-473 (1983).
46. Lin F. The protective effects of the large-scale use of PHKC rabies vaccine in humans in China. Bull. Wld. Hlth. Org. 68, 449-454 (1990).
47. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621 (1961).
48. Hayflick L. The coming of age of WI-38. Adv. Cell Culture 3, 303-316 (1984).
49. Hayflick L, Plotkin SA, Norton TW, Koprowski H. Preparation of poliovirus vaccines in a human fetal diploid cell strain. Am. J. Hyg. 75, 240-258 (1962).
50. Fernandes MV, Wiktor TJ, Koprowski H. Mechanism of the cytopathic effect of rabies virus in tissue culture. Virology 21, 128-131 (1963).
51. Wiktor TJ, Fernandes MV, Koprowski H. Cultivation of rabies virus in human diploid cell strain WI-38. J. Immunol. 93, 353-366 (1964).
52. Petricciani J, Sheets R. An overview of animal cell substrates for biological products. Biologicals 36, 359-362 (2008). (Pubitemid 50224400)
53. Jacob JP, Jones CM, Baille JP. Characterization of a human diploid cell designated MRC-5. Nature 277, 168 (1970).
54. Bernard KW, Smith PW, Kader FJ, Moran MJ. Neuroparalytic illness and human diploid cell rabies vaccine. JAMA 248, 3136-3138 (1982). (Pubitemid 13254854)
55. Boe E, Nyland H. Guillain-Barré syndrome after vaccination with human diploid cell rabies vaccine. Scand. J. Infect. Dis. 12, 231-232 (1980). (Pubitemid 10086370)
56. Burgoyne GH, Kajiya KD, Brown WE, Mitchell JR. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J. Infect. Dis. 152, 204-210 (1985). (Pubitemid 15038854)
57. Centers for Disease Control and Prevention. Current trends rabies vaccine, adsorbed: a new rabies vaccine for use in humans. MMWR Morb. Mortal. Wkly Rep. 37, 217-218, 223 (1988).
58. Lavender JF, Frank RM. Zonal-centrifuged purified duck embryo cell culture rabies vaccine for human vaccination. Appl. Microbiol. 22, 358-365 (1971).
59. Ashwathnarayana DH, Madhusudana SN, Sampath G et al. A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purified Vero cell rabies vaccine (PVRV, Verorab). Vaccine 28, 148-151 (2010).
60. Torlone V, Titoli F. Development and diffusion of the rabies virus (Flury HEP strain) in embryonated egg and itsmultiplication on trypsinized cells of infected chick embryo (In Italian). Nuovi. Ann. Ig. Microbio. 15, 263-264 (1964).
61. Kondo A. Growth characteristics of rabies virus in primary chicken embryo cells. Virology 27, 199-204 (1965).
62. Barth R, Gruschkau H, Bijok U et al. A new inactivated tissue culture rabies vaccine for use in human evaluation of PCEC-vaccine by laboratory tests. J. Biological Stand. 12, 29-46 (1984). (Pubitemid 14187935)
63. Centers for Disease Control and Prevention. Notice to readers availability of new rabies vaccine for human use. MMWR Morb. Mortal. Wkly Rep. 47, 12, 19 (1998).
64. Sedwick WD, Wiktor TJ. Reproducible plaguing system for rabies, lymphocytic choriomeningitis and other ribonucleic acid viruses in BHK-21/13S agarose suspensions. J. Virol. 1, 1224-1226 (1967).
65. Yasumura Y, Kawakita Y. Study of SV40 in tissue culture (in Japanese). Nippon Rinsho 21, 1201-1205 (1963).
66. Debbie JG, Andrulonis JA, Abelseth MK. Rabies antibody determination by immunofluorescence in tissue culture. Infect. Immun. 5, 902-904 (1972).
67. Buckley SM, Tignor GH. Plaque assay for rabies serogroup viruses in Vero cells. J. Clin. Microbiol. 1, 241-242 (1975).
68. Pullen K, Johnston MD, Philips AW, Ball GD, Finter WB. Very large scale suspension cultures of mammalian cells. Dev. Biol. Standard 60, 175-177 (1984).
69. Roumiantzeff M, Ajjan N, Branche R et al. Rabies vaccine produced in cell culture: production and control and clinical results. In: Applied Virology. Kurstak (Ed.). Academic Press, FL, USA, 241-296 (1984).
70. Fournier P, Montagnon B, Vincent-Falquet JC, Ajjan N, Drucker J, Roumiantzeff M. A new vaccine produced from rabies virus cultivated on Vero cells. In: Improvements in Rabies Post-Exposure Treatment. Vodopija I, Nicholson KG, Smerdel S, Bijok U (Eds). Institute of Public Health, Zagreb, Croatia (1985).
71. Suntharasamai P, Chanthavanich P, Warrell MJ et al. Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens. J. Hyg. 96, 483-489 (1986). (Pubitemid 16091977)
72. Centers for Disease Control and Prevention. Rabies in a laboratory worker - New York. MMWR Morb. Mortal. Wkly Rep. 26, 183-184 (1977).
73. Sacramento D, Badrane H, Bourhy H, Tordo N. Molecular epidemiology of rabies virus in France: comparison with vaccine strains. J. Gen. Virol. 73, 1149-1158 (1992).
74. Pará M. An outbreak of post-vaccinal rabies (Rage de Laboratoire) in Fortaleza, Brazil, in 1960: residual fixed virus as the etiological agent. Bull. Org. mond. Santé/ Bull. World Health Organ. 33, 177-182 (1965).
75. Abelseth MK. Further studies on the use of ERA rabies vaccine in domestic animals. Can. Vet. J. 8, 221-227 (1967).
76. Fehlner-Gardiner C, Nadin-Davis S, Armstrong J, Muldoon F, Bachmann P, Wandeler A. ERA vaccine-derived cases of rabies in wildlife and domestic animals in Ontario, Canada, 1989-2004. J. Wildl. Dis. 44, 71-85 (2008). (Pubitemid 351575049)
77. Follmann EH, Ritter DG, Baer GM. Evaluation of the safety of two attenuated oral rabies vaccines, SAG1 and SAG2, in six Arctic mammals. Vaccine 14, 270-273 (1996). (Pubitemid 26126429)
78. Wang C, Zhang X, Song Q, Tang K. Promising rabies vaccine for postexposure prophylaxis in developing countries, a purified Vero cell vaccine produced in China. Clin. Vaccine Immunol. 17, 688-690 (2010).
79. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J. 13, 4195-4203 (1994). (Pubitemid 24295191)
80. Inoue K, Shoji Y, Kurane I, lijima T, Sakai T, Morimoto K. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods 107, 229-236 (2003). (Pubitemid 36005508)
81. Wu X, Franka R, Velasco-Villa A, Rupprecht CE. Are all lyssavirus genes equal for phylogenetic analyses? Virus Res. 129, 91-103 (2007). (Pubitemid 47588425)
82. Wu X, Rupprecht CE. Glycoprotein gene relocation in rabies virus. Virus Res. 131, 95-99 (2008). (Pubitemid 350245535)
83. Shantavasinkul P, Tantawichien T, Wilde H et al. Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clin Infect Dis. 50, 56-60 (2010).
84. Sudarshan MK, Madhusudana SN, Mahendra BJ. Post-exposure prophylaxis with purified Vero cell vaccine during pregnancy-safety and immunogenicity. J. Commun. Dis. 31, 229-236 (1999).
85. Ajjan N, Pilet C. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine 7, 125-128 (1989). (Pubitemid 19089668)
86. Arai YT, Montalban CS. Comparative studies on chick embryo cell rabies vaccine and human diploid cell vaccine: preexposure use and purity of the vaccines. Southeast Asian J. Trop. Med. Public Health 24, 747-750 (1993). (Pubitemid 24193460)
87. Dietzschold B, Hooper DC. Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV). Vaccine 16, 1656-1659 (1998). (Pubitemid 28366078)
88. Sabchareon A, Lang J, Attanath P et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin. Infect. Dis. 29, 141-149 (1999). (Pubitemid 29336816)
89. Jones RL, Froeschle JE, Atmar RL et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 19, 4635-4643 (2001). (Pubitemid 32800745)
90. Madhusudana SN, Sanjay TV, Mahendra BJ et al. Comparison of safety and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML. Hum. Vaccine 2, 200-204 (2006). (Pubitemid 44786801)
91. WHO. The immunological basis for immunization series. Rabies 17, 1-23 (2011).
92. Cox JH, Schneider LG. Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. J. Clin Microbiol. 3, 96-101 (1976).
93. Harverson G. Post-exposure intradermal antirabies vaccine: a cheaper alternative for developing countries. Trop. Doct. 14, 67-70 (1984). (Pubitemid 14149984)
94. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP). Supplementary statement on pre-exposure rabies prophylaxis by the intradermal route. MMWR Morb. Mortal. Wkly Rep. 31, 285, 279-280 (1982).
95. WHO Expert Committee on rabies. World Health Organ. Tech. Rep. Ser. 824, 1-84 (1992).
96. Osinubi MO, Wu X, Franka R et al. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modification. Vaccine 27, 7214-7218 (2009).
97. Gupta PK, Dahiya SS, Kumar P et al. Sindbis virus replicon-based DNA vaccine encoding rabies virus glycoprotein elicits specific humoral and cellular immune responses in dogs. Acta Virol. 53, 83-88 (2009).
98. Kaur M, Rai A, Bhatnagar R. Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge. Vaccine 27, 2128-2137 (2009).
99. Chen H, Xiang ZQ, Li Y et al. Adenovirusbased vaccines: comparison of vectors from three species of adenoviridae. J. Virol. 84, 10522-10532 (2010).
100. Bouet-Cararo C, Contreras V, Fournier A et al. Canine adenoviruses elicit both humoral and cell-mediated immune responses against rabies following immunization of sheep. Vaccine 29, 1304-1310 (2011).
101. Wayer J, Rupprecht CE, Nel LH. Poxvirus-vectored vaccines for rabies - a review. Vaccine 27, 7198-7201 (2009).
102. Smith TG, Wu X, Franka R, Rupprecht CE. Design of future rabies biologics and antiviral drugs. Adv. Virus Res. 79, 345-363 (2011).
103. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Effective preexposure and postexposure of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106, 11300-11305 (2009).
104. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 84, 2820-2831 (2010).
105. Wu X, Franka R, Henderson H, Rupprecht CE. Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. Vaccine 29, 4195-4201 (2011).
106. Lang J, Feroldi E, Vien NC. Pre-exposure purified Vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam. J. Trop. Pediatr. 55, 26-31 (2009).